91³Ô¹Ï

Abstract

Introduction: Treatment of hepatitis C was until 2011 dual therapy (peg-interferon and ribavirin) before two direct antiviral agents, telaprevir and boceprevir were available. At time of dual therapy, only 14% of inmates with hepatitis C were treated. Objectives and methods: Objective was to study in national survey, over 2011/2012, number of patients treated in MJU (Medical Jailhouse Unit), with dual or triple therapy. Preliminary results: Hepatitis screening was systematically proposed in 100% of MJU; 27622 serologies C were annually realized with rate of 3.1% positivity; followed patients were 1544 in 2011 and 1321 in 2012 (4.2%); 49% of MJU had regular hepatology consultation; to evaluate liver fibrosis 227 FIBROSCAN* and 511 FIBROTEST were realized in 2012. In 2011, 261 patients were treated (16.9%) and in 2012, 332 patients (25%). Triple therapy constituted 12% of treatment in 2011, 39% in 2012 (telaprevir 78%, boceprevir 28%); 42% of the MJU introduced no treatment in 2011 (77% any triple therapy) and 56% in 2012 (66% any triple therapy). Conclusions: Frequent positive patients VHC in jailhouses, good screening and diagnosis and using widely not invasive methods of fibrosis but different practices for hepatitis treatment between MJU treating a lot of patients and MJU treating none. Compared with the study of 2005, percentage of treated patients was doubled but percentage of MJU involved decreased to 45%.

Biography

André-Jean Remy has completed his PhD at the age of 31 years from University of Montpellier, France. He is department head of Hepato/Gastroenterology and Medical Jailhouse Unit of Perpignan Hospital. He has published 66 papers in reputed medical journals and national/international congresses, specially on viral hepatitis in inmates and drugs users.